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BLyS (also called BAFF, TALL-1, THANK, and zTNF4), round of screening, many positive pools contained the
known BLyS receptors, TACI and BCMA, as confirmeda TNF superfamily member, binds two receptors,
TACI and BCMA, and regulates humoral immune by PCR with gene-specific primers. However, another
pool was identified that contained neither TACI norresponses [1–7]. These two receptors also bind
APRIL [7–10], another TNF superfamily member. The BCMA. We subjected this pool to additional rounds of
screening to obtain a single cDNA clone capable of confer-results from TACI/ and BCMA/ mice suggest
the existence of additional receptor(s) for BLyS. The ring BLyS binding activity to transfected COS7 cells.
Sequencing revealed a single open reading frame thatTACI knockout gives the paradoxical result of B
cells being hyperresponsive, suggesting an encoded a novel protein with a single putative transmem-
brane region (Figure 1a).inhibitory role for this receptor [11, 12], while
BCMA null mice have no discernable phenotype [13].
Here we report the identification of a third BLyS Database searches revealed a putative murine ortholog
receptor (BR3; BLyS receptor 3). This receptor is (GenBank accession number AK008142). Similar to hu-
unique in that, in contrast to TACI and BCMA, BR3 man BR3 (hBR3), murine BR3 (mBR3) possesses only
only binds BLyS. Treatment of antigen-challenged four cysteines. Overall, hBR3 and mBR3 exhibited 56%
mice with BR3-Fc inhibited antibody production, identity and 66% similarity. Both hBR3 and mBR3 lack
indicating an essential role for BLyS, but not APRIL, anN-terminal putative signal peptide, indicating that they
in this response. A critical role for BR3 in B cell are type III transmembrane proteins [16]. The intracellu-
ontogeny is underscored by our data showing that lar domain of BR3 is highly conserved between hBR3
the BR3 gene had been inactivated by a discrete, and mBR3 (Figure 1a). Northern blot analysis indicated
approximately 4.7 kb gene insertion event that that both hBR3 and mBR3 were highly expressed in the
disrupted the 3 end of the BR3 gene in A/WySnJ spleen (Figure 1b).
mice, which lack peripheral B cells.
The prominent expression of BR3 in the spleen and in
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ferred strong binding to AP-BLyS, but not AP-APRIL
(Figure 2a and data not shown). In contrast, bothAP-BLyS
and AP-APRIL bound TACI-transfected cells (Figure 2a,
lower panel). A human Fc fusion protein based on theResults and discussion
To identify additional receptor(s) for BLyS, we used an hBR3 ectodomain (hBR3-hFc) bound cells transfected
with a plasmid encoding the full-length transmembraneexpression-cloning strategy [14, 15]. Mature soluble hu-
man BLyS (amino acids 136–285) was generated by fusion form of BLyS, but not cells expressing APRIL (Figure 2b).
Murine BR3-Fc, like hBR3-hFc, also only bound BLyS-at its N terminus to human placental alkaline phosphatase
(AP-BLyS). This chimeric ligand was used for screening transfected but not APRIL-transfected COS 7 cells (data
not shown). To confirm the interaction between BR3a human spleen cDNA expression library transfected as
pools into COS 7 cells [6]. As expected after the first and BLyS, we performed coimmunoprecipitation (co-IP)
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Figure 1
(a) Sequence alignment of human and murine
BR3. Amino acids that are identical in human
and murine BR3 are shown in bold. Conserved
amino acids are indicated by a plus sign. The
region containing four cysteine residues is
underlined, and the predicted membrane-
spanning region is doubly underlined. (b)
Northern blot analysis of BR3. Human (left) and
mouse (right) multiple tissue Northern blots
(Clontech) were probed with 32P-labeled
cDNA fragments corresponding to the coding
region of human or murine BR3. (c) PCR
analysis of human multiple tissue cDNA panel
(Clontech). cDNA fragments were amplified
with gene-specific primers. Lanes 1–9: 1,
PBL; 2, resting CD4 cells; 3, activated
CD4 cells; 4, resting CD8 cells; 5,
activated CD8 cells; 6, resting CD19
cells; 7, activated CD19 cells; 8, lymph
node; 9, spleen.
experiments (Figure 2c). Flag-BLyS but not Flag-APRIL and GITRL (data not shown). These results show that,
unlike TACI and BCMA, BR3 specifically binds BLySwas readily detected in complex with hBR3-hFc, whereas
TACI-hFc bound both Flag-BLyS and Flag-APRIL. Fur- but not APRIL.
thermore, BR3-Fc failed to bind cells expressing several
other TNF family members, including CD27L, CD30L, It has previously been shown that treating antigen-chal-
lenged mice with TACI-Fc or BCMA-Fc suppresses anti-CD40L, EDA-A1, EDA-A2, 4-1BBL, FasL, Apo2L/
TRAIL, Apo3L/TWEAK, OX-40L, RANKL/TRANCE, body production [6]. Since TACI-Fc and BCMA-Fc bind
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Figure 2
BR3 is a specific receptor for BLyS but not
for APRIL. (a) COS 7 cells transfected with
hBR3 (1, 2) or TACI (3, 4) were incubated
with conditioned medium containing AP-
BLyS (1, 3) or AP-APRIL (2, 4). Cells were
washed, fixed, and stained for the AP activity
in situ. (b) COS 7 cells transfected with BLyS
(1, 2) or APRIL (3, 4) were incubated with
BR3-hFc (1, 3) or TACI-hFc (2, 4). Cells were
washed and fixed, and the bound receptor-
hFc protein was detected with a biotinylated
goat anti-human antibody followed by Cy3-
streptavidin. (c) BR3-hFc (lanes 1, 2) or TACI-
hFc (lanes 3, 4) were incubated with Flag-
BLyS (lanes 1, 3) or Flag-APRIL (lanes 2, 4).
The receptor-Fc fusion proteins precipitated
with protein-A-agarose were subjected to
immunoblotting with anti-Flag antibody.
Equivalent amounts of ligand (middle panel)
or receptor-hFc (bottom) were used in the
binding experiment. (d) TNP-specific IgG1
production from control Ig-treated (white bar)
and from BR3-Fc-treated (black bar) mice.
Data represent five mice in each group, given
in mean  SEM, p  0.005.
both BLyS and APRIL, it was only possible to surmise was easily discernable (Figure 3a). This result suggested
alteration of the BR3 gene in A/WySnJ mice.that either BLyS or APRIL or both were important in
mediating the antibody response. However, with the avail-
ability of BLyS-specific BR3-Fc, it is possible to distin- To determine the nature of the BR3 gene mutation, we
guish the in vivo roles of BLyS and APRIL in the B designed a PCR strategy based on the genomic sequence
cell response to antigen challenge. BR3-Fc, in contrast to to amplify products of various lengths, as outlined in Fig-
control-Fc, substantially inhibited the production of ure 3b. When primers P1 (18 bp upstream of ATG) and
TNP-specific IgG1 in mice immunized with TNP-Ficoll P1AS or P2AS (36 bp upstream of TAG) were used for
(Figure 2d). amplification, PCR products from the A/J and A/WySnJ
strains were the same size (Figure 3c,d). This result indi-
cates that the BR3 gene up to 36 bp upstream of theThe human BR3 gene maps to chromosome 22, which is
TAG (stop codon) is unaltered in the A/WySnJ strain.syntenic to the middle region of chromosome 15 in mice
However, when the region from 109 bp upstream of TAG(data not shown). Interestingly, a gene locus termed Bcmd
to 14 bp downstream of TAG was amplified with primers(B cell maturation defect) also has been reported to map
P2 and P3AS, a PCR product of expected size (172 bp)to the middle region of mouse chromosome 15, which is
was amplified from the A/J strain, but the A/WySnJ strainresponsible for the profound defect in the B cell matura-
yielded an approximately 4.9 kb product. This result indi-tion in the mouse A/WySnJ strain. A related A/J strain,
cates that there was an insertion of approximately 4.7 kbhowever, which does not possess a single autosomal co-
in the region between P2AS and P3AS, which are 53 bpdominant Bcmd locus, has no deficit in peripheral B cells
apart. Additional primer sets P2/P4AS, P2/P5AS, and P2/[21–23]. To determine if the gene defect in A/WySnJ
P6AS all amplified products of expected size, as shownmice, as defined genetically by the Bcmd locus, was in the
in Figure 3c, confirming insertion of an approximately 4.7gene encoding BR3, we performed RT-PCR to detect
kb in the BR3 gene of A/WySnJ mice.the transcript for BR3. RT-PCR analysis failed to reveal
the presence of BR3 transcript corresponding to the com-
plete coding region in splenic or CD19 B cell RNA To determine the exact location of the insertion within
the BR3 gene of A/WySnJ mice, we amplified and subse-from A/WySnJ mice, while the transcript for TACI control
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Figure 3
Analysis of BR3 transcripts and gene in A/WySnJ mice. (a) Analysis were used for amplifying genomic DNA isolated from A/J or
of BR3 transcripts in splenic cells (lanes 1, 2) or CD23 B cells (lanes A/WySnJ mice. The sizes of the PCR products are summarized in (c).
3, 4). RT-PCR was performed with total RNA isolated from A/J (lanes (e) Insertion mutation of BR3 gene in A/WySnJ mice. Sequencing
1, 3) or A/WySnJ mice by the use of (top) murine BR3- or (bottom) of the PCR (Primers P2 and P4AS) product amplified from genomic
murine TACI-specific primers. (b) Location of primers used in PCR DNA of A/WySnJ mice revealed an insertion event that deleted the
analysis of the BR3 gene. The initiation and stop codons are last eight amino acids in the C-terminal coding region of the BR3
indicated as ATG and TAG, respectively. (c,d) Primers as indicated gene.
quently sequenced a 5.1 kb PCR product from A/WySnJ receptors, results from TACI and BCMA knockout mice
have added additional complexity to the system. Themice with primers P2 and P4AS. Alignment of the A/J
and A/WySnJDNA sequences revealed that theBR3 gene TACI null mutation leads to massive accumulation and
activation of B cells in vivo, while BCMA/ mice havein A/WySnJ mice is missing a region encoding the last
eight amino acids of the gene (Figure 3e). no obvious phenotype [11–13]. Thus, TACI/mice give
the paradoxical result of hyperproliferation, suggesting an
inhibitory role for this receptor, while the significanceRecent reports have established a key role for BLyS in the
regulation of humoral immunity; however, the individual of BCMA remains to be defined. These results clearly
indicate the existence of an additional receptor(s) forcontributions of its receptors, TACI and BCMA, are still
unknown. Rather than defining the discrete roles of these BLyS. In the present report, a novel BLyS receptor identi-
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fied by expression cloning is described that plays a key gaged by BR3 is likely responsible for the B cell-prolifera-
tive effect of BLyS, and in its absence, B cell homeostasisrole in B cell development and function.
is compromised.
Although BR3, like TACI and BCMA, binds BLyS and
Materials and methodsis expressed on B cells, this receptor is unique in other
cDNA expression vectorsfeatures. First, sequence alignments indicate that BR3 is
A sequence encoding human placental alkaline phosphatase (AP) andnot a typical member of the TNF receptor superfamily,
either human BLyS (amino acids 136–285) or human APRIL (aminowhich is defined by the presence of characteristic cyste- acids 105–250) was amplified by PCR and cloned in frame into the
ine-rich repeats within the extracellular ligand binding expression vector pFlag-CMV1 (Sigma) with AP at the N terminus of
BLyS or APRIL (AP-BLyS/AP-APRIL). Expression constructs for Flag-domain. These pseudorepeats (40 amino acids) are typi-
BLyS or Flag-APRIL were generated by direct cloning of BLyS (aminocally defined by three intramolecular disulfide bridges
acids 136–285) or APRIL (amino acids 105–250) into pFlag-CMV1.formed by six highly conserved cysteines [24]. BR3 has hBR3-hFc and TACI-hFc were constructed by the cloning of hBR3
only four cysteine residues in its ectodomain. It should (amino acids 2–62) or TACI (amino acids 2–166) into the pRK5 vector
engineered with an upstream heterologous signal sequence (pre-protryp-be noted, however, that TACI, BCMA, and FN14 also
sin amino acids 1–17 from pFlag-CMV1) and a downstream humancontain a cysteine-rich module composed of four cysteine
IgG1 Fc domain.residueswith the consensus sequence xxCx2–3Cx5–8CxxCxx.
BR3 contains a similar pattern of cysteines except for the Expression cloning of BR3
first cysteine, which is followed by four amino acids. This Expression cloning was performed as described [6]. AP-BLyS was ex-
suggests that the overall tertiary structure of these recep- pressed in human embryonic kidney 293 cells. Conditioned medium
from transfected cells was filtered (0.45 M), stored at 4C in a buffertors may be similar.
containing 20 mM HEPES (pH 7.0) and 1 mM sodium azide, and subse-
quently used for cell staining. A cDNA expression library was constructed
Additional unique features of BR3 are that it only binds with PolyA mRNA from human spleen. The primary transformants were
divided into pools of approximately 1000 colonies. For each pool, aBLyS and that treatment of antigen-challenged mice with
glycerol stock was prepared. Miniprep DNA (Qiagen) from each poolBR3-Fc inhibits antibody production, indicating an essen-
was transiently transfected into COS 7 cells in 12-well plates by the
tial role for BLyS, but not APRIL, in this response. These use of lipofectamine (GIBCO-BRL). After 36-48 hr, cells were incubated
results underscore the importance of BLyS in the B cell with AP-BLyS-conditioned medium and stained for AP activity in situ. A
positive pool was broken down successively into smaller pools until aresponse and suggest no major role for APRIL in antigen-
single positive clone was identified.specific antibody production. Furthermore, the data also
support the importance of BR3 in B cell-mediated effects.
In vivo antigen-specific antibody production
Two groups (five per group) of 5-week-old C57BL/6 mice were immu-
nized intraperitoneally (i.p.) with 100 g of TNP-Ficoll (Biosource Tech-Compelling data for the functional significance of BR3
nologies). One group was given 100 g of control Ig, while the othercome from the study of B cell-deficient A/WySnJ mice
group received 100 g of BR3-Fc daily. Seven days later, total TNP-that, unlike the related A/J strain, possess a single autoso- specific IgG1 present in the mice sera was measured. TNP-specific
mal codominant locus, termed Bcmd, that is responsible IgG1 antibodies were quantified with ELISA plates coated with TNP-
for the profound deficit in peripheral B cells [21–23]. conjugated BSA (Biosource Technologies). Bound antibodies were
detected with alkaline phosphatase-conjugated goat anti-mouse IgG1Splenic B cells from A/WySnJ mice do not exhibit a prolif-
(Pharmingen).erative response to recombinant BLyS either in vitro or in
vivo (our submitted manuscript). Additionally, A/WySnJ Acknowledgements
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